AU622101B2 - Oral administration capsule with a nicotine-containing fluid medium - Google Patents
Oral administration capsule with a nicotine-containing fluid medium Download PDFInfo
- Publication number
- AU622101B2 AU622101B2 AU81712/87A AU8171287A AU622101B2 AU 622101 B2 AU622101 B2 AU 622101B2 AU 81712/87 A AU81712/87 A AU 81712/87A AU 8171287 A AU8171287 A AU 8171287A AU 622101 B2 AU622101 B2 AU 622101B2
- Authority
- AU
- Australia
- Prior art keywords
- nicotine
- capsule
- document
- fluid medium
- date
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 64
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 63
- 229960002715 nicotine Drugs 0.000 title claims abstract description 63
- 239000002775 capsule Substances 0.000 title claims abstract description 46
- 239000012530 fluid Substances 0.000 title claims abstract description 22
- 230000000391 smoking effect Effects 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 7
- 210000002200 mouth mucosa Anatomy 0.000 claims description 11
- 235000019504 cigarettes Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000000779 smoke Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 4
- 235000019640 taste Nutrition 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 230000009747 swallowing Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 235000003642 hunger Nutrition 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 241001136792 Alle Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 description 1
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101150037769 TRX2 gene Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oral administration capsule with a nicotine-containing, fluid medium. The capsule can be opened by pressing it with the teeth, the amount of nicotine is between 0.1 and 10 mg, the medium contains additives to improve its flavour and consistency and its pH is between 6 and 10. A capsule is thus obtained that can have various uses, especially to reduce addiction to smoking and to control feelings of hunger.
Description
AU-AI-6M72?87, P TWELTORGANISATION FOR GITGSEGNU INTERNATIONALE ANMVE N FE E VERTRAG OJBER DIE INTERNATIONALE ZUSA' N 13 AU DEa EBI] DES PATENTWESENS (PCT) (51)Intrnaiona~ Ptenklasifiatin 4(11) Internationale Veroffentlichungsnummer: WO 88/ 03803 A61K 31/465, 9/48, 9/66 Al (43) Internationales Verboffentl ich ungsdatumr: 2. Juni 1988 (02.06.88) (21) Internationales Aktenzeichen: PCT/DE87/00507 (81) Bestiinmungsstaaten: AT (europAisches Patent), AU, BE (europdisches Patent), BR, CH (europaisches Pa- (22) Internationales Anmneldedatum: tent), DE (europaisches Patent), DK, FR (europiii- 6. November 1987 (06.11.87) sches Patent), GB (europaisches Patent), HUJ, IT (europdisches Patent), JP, KR, LU (europaisches Patent), NL (europdisches Patent), SE (europaisches Patent), (31) Priorititsaktenzeichenm P 3639 418.1 SU, us.
(32) Prioritlitsdatumn: 18. November 1986 (18.11.86) Verdffentlicht (33) Priorititsland: DE Mit internationalem Recherchenbericht.
(71) Anmielder (fur alle Bestimmungsstaaren ausser US): FORSCHUNGSGESELLSCHAFT RAUCHEN UND GESUNDHEIT MBH [DE/DE]; Frauenthal 2, r.JP 21 UL18 D-2000 Hamburg 13 K I .21JL18 (72) Erfinder; und ASRLA Erfinder/Anmelder (nur ftir US) ADLKOFER, Franz 16JN18 [DE/DE]; Parallelstrasse 18, D-1000 Berlin 45 (DE).16JN98 (74) Anwalte: JAN DER, Dieter usw.; Kurfiirstendamm 66, PATENT OFFICE D-1000 Berlin 15 (DE).
(54) Title: ORAL ADMINISTRATION CAPSULE WITH A NICOTINE-CONTAINING FLUID MEDIUM (54) Bezeichnung: ORAL EINZUNEHMENDE KAPSEL MIT EINEM NIKOTINHALTIGEN, FLUSSIGEN MIT-
TEL
(57) Abstract An oral administration capsule with a nicotine-containing, fluid medium. The capsule can be opened by pressing it with the teeth, the amount of nicotine is between 0. 1 and 10 mg, the medium contains additives to improve its flavour and consistency and its pH is between 6 and 10. A capsule is thus obtained that can have various uses, especially to reduce addiction to smoking and to control feelings of hunger.
(57) Zusammenfassung Die Erfindung besteht darin, dali die Kapsel durch Druck der Ziihne gec~ffnet werden kann, dali die Menge an Nikotin zwisclien 0,1 und 10 mg liegt, dali das Mittel Zusatzstoffe zur Geschmacks- und Vertrdglichkeitsverbesserung enthiilt und dali der pH--Wert des Mittels zwischen 6 und 10 liegt. Auf diese Weise wird eine oral einzunehmende Kapsel geschaffen, die in vielfiiltiger Hinsicht insbesondere zur Raucherentw6hnung und zumn Appetitztigeln verwendet werdenmkann.
'k4
L
J
(J
-1 A METHOD OF ADMINISTERING NICOTINE BY MEANS OF A BITE RUPTURABLE CAPSULE IN WHICH THERE IS A NICOTINE-CONTAINING FLUID MEDIUM.
The invention provides a capsule in which there is a nicotine-containing fluid medium. The capsule is of the type which can be ruptured by biting to rapidly administer the contents of the capsule orally.
German Offenlegungsschrift 36 06 892 discloses a nicotine containing fluid medium in a capsule having a minute hole and the capsule contents are expressed slowly and continuously in the mouth of the person through the minute hole in the capsule wall by reason of osmotic pressure (page :13, para. This manner of administration is not satisfactory as it does not simulate the way in which a S' 15 smoker obtains nicotine from a cigarette.
j German Offenlegungsschrift 36 06 892 does not disclose the amount of nicotine in the capsule, nothing about any S: additives and nothing about the pH of the contents.
o•4 S "i 4 4*
L
la The present invention allows a person to be exposed to nicotine in a manner to provide a sensation similar to that experienced when smoking a cigarette.
The invention can be broadly said to provide a method of administering nicotine to a human in a manner to induce blood and tissue uptake of nicotine and rapid transfer of the nicotine to the brain and thereby simulate the effect achieved by smoking a cigarette and inhaling the smoke, said method comprising the steps of; providing a bite rupturable capsule to be taken
S
S
orally, providing a capsule filling which is a fluid medium which includes as the essential component nicotine in an amount between 0.1 and 10mg and which has a pH of between 7 15 and 10 with the nicotine amount and the fluid medium pH preset to at least permit a nicotine uptake by the user comparable with that resulting from smoking a cigarette and inhaling the smoke, placing the filled capsule in the mouth of a user and whilst in the mouth of the user biting the capsule to cause it to rupture to substantially completely discharge said nicotine containing fluid medium directly over the oral mucosa through which the nicotine rapidly enters the blood of the user, I CE :ii:..A r: Ib maintaining the capsule filling in direct contact with the oral mucosa for a prolonged period of time sufficient to permit absorption of nicotine through the oral mucosa to the extent at least comparable with smoking a S cigarette and inhaling the smoke, disposing of the contents of the mouth of the user after said period of time.
10 .o 1• oo o I 1:5 The invention further provides a bite rupturable capsule for use in the abovs method where the capsule contains a fluid medium including as the essential component nicotine in an amount between 0.1 and 10mg and where the fluid medium has a pH of between 7 and The fluid medium in the capsule preferably includes additives to improve the taste and tolerability of the fluid medium.
0: rsiB.,, tl~ s::l
P:
~31 '-id L i When a capsule of this type is taken and bitten open the contents thereof pour over the oral mucosa with the consequence that the nicotine enters, via the latter, the body and the blood circulation. The person experiences a powerful dose of nicotine, with the nicotine quickly reaching the brain. The amount of nicotine absorbed is determined by the preset nicotine content of the capsule and .the preset pH of the medium. The amount is comparable to the amount absorbed by a smoker when he smokes a cigarette 10 and inhales the smoke.
i O S Thef additivesR, provided ensure that the unpleasant and astringent taste of the nicotine is moderated.
It is important that the nicotine-containing fluid remains -in the mouth for some minutes. With this procedure an amount of nicotine of up to 1.5 mg is absorbed within ego• minutes from 1.5 ml of solution which contains 3.0 mg of nicotine and has a pH of 8.0. This amount approximately corresponds to that absorbed when a moderately strong cigarette is smoked. The amount of nicotine remaining in solution can be expectorated or swallowed after a certain time which is determined by the person taking the capsule.
Swallowing results in an additional increase in nicotine in blood and tissue, which increase takes place slowly, in
(L
;r ft contrast to the increase after nicotine absorption in the mouth, and thus enhances the initial effect.
German Offenlegungsschrift 32 41 437 discloses a nicotinecontaining spray for oral use. However, nicotine administration using a spray is relatively unpleasant.
British Patent 15 28 391 discloses that the dose unit of nicotine acting on the oral mucosa is between 0.1 and 10.0 mg. However, this relates to an aerosol which is sprayed into the mouth. Moreover, no additives to improve the taste
S.
10 and tolerability are provided, and finally nothing is disclosed about the pH of the medium either.
B
German Offenlegungsschrift 34 01 763 discloses a nicotinecontaining medium for administration in the nose. This administration is also unpleasant, because the nasal mucosa is more sensitive than the oral mucosa. In addition, there is no guarantee that the medium remains in the nasal cavity.
Goo*
S.
German Offenlegungsschrift 34 38 284 discloses a nicotinereleasing depot plaster. However, no powerful dose of nicotine is possible with this. The absorption of nicotine takes place very slowly and in an uncontrolled manner.
"Transdermal Administration of Nicotine" ("Drug and Alcohol i I r; I i I I I C1! I 4 4- Dependence", 13, 1984, pages 209-213) likewise discloses a nicotine medium acting via the skin. Absorption of nicotine in a rapid manner is not possible in this case either.
Belgian Patent 899 037 discloses a suckable sweet which contains nicotine. Absorption of nicotine in a rapid manner is not possible hereby either.
Capsules containing any desired pharmaceuticals have also Sbeen disclosed Gstirner, "Einfuhrung in die Verfaahrens- 0 0 technik der Arzneiformung" (Introduction to the Technology of Producing Drug Forms), 1973, pages 177-181). However, the capsules in this case do not contain nicotine.
SeeS..
0 Moreover, biteable capsules have also been disclosed (B.
S°
06 0 Helwig, "Moderne Arzneimittel" (Modern Pharmaceuticals).
ee 1980, page 815). However, the capsules in this case do not contain nicotine either.
Many scientific findings indicate that nicotine, in the dose absorbed during smoking, has no pathogenic properties. In particular, it appears not to contribute to the development of so-called smokers' diseases.
Nicotine exerts a variety of effects on the nervous system and the psychovegetative functions. It can be used for 1 5 stopping smoking and as a medicament for the following indications: *see*: on*@ *0900 so 1 0
S
0
S*
*0 Obesity Parkinson's disease Alzheimer's disease Anxiety neuroses Cerebral sclerosis Ulcerative colitis All these indications are combined with each other via acetylcholine receptor organs.
S
*000 0* @0 0 0 *00S 0S e
S
The pharmacological importance of nicotine for the indications mentioned in the present case is based on its properties as choline preparation with mainly central, but also peripheral effects. Nicotine has also an indirect influence via its linkage to cholinergic receptor organs on the release of the most known neuro-transmitters, because the cholinergic system is in correlation with the other transmitter systems. All diseases mentioned in the present case are influenced by one or several of the affected receptor systems.
'l
'I
Claims (7)
1. A method of administering nicotine to a human in a manner to induce blood and tissue uptake of nicotine and rapid transfer of the nicotine to the brain and thereby simulate the effect achieved by smoking a cigarette and inhaling the smoke, said method comprising the steps of; providing a bite rupturable capsule to be taken orally, 9O *Vso: a .0 providing a capsule filling which is a fluid medium 10 which includes as the essential component nicotine in an amount between 0.1 and 10mg and which has a pH of between 7 and 10 with the nicotine amount and the fluid medium pH preset to at least permit a nicotine uptake by the user comparable with that resulting from smoking a cigarette and 15 inhaling the smoke, placing the filled capsule in the mouth of a user and whilst in the mouth of the user biting the capsule to cause it to rupture to substantially completely discharge said nicotine containing fluid medium directly over the oral mucosa through which the nicotine rapidly enters the blood of the user, 10 4 -4 7 maintaining the capsule filling in direct contact with the oral mucosa for a prolonged period of time sufficient to permit absorption of nicotine through the oral mucosa to the extent at least comparable with smoking a cigarette and inhaling the smoke, disposing of the contents of the mouth of the user after said period of time.
2. The method as claimed in claim 1 where the disposal step is achieved by swallowing said contents to allow absorption of further nicotine from said fluid medium into *0* the blood where such absorption is at a rate less than that S at which nicotine enters the blood through the oral mucosa and thereby achieve an increase in the nicotine level in the blood and an enhancement of the effect of the rapid :absorption of nicotine through the oral mucosa.
3. The method claimed in claim 1 or claim 2 including the step of including additives in the capsule filling to improve the taste and tolerability of the capsule filling.
4. A bite rupturable capsule 4e. usecXin the method of any one of claims 1 to 3 where said capsule contains a fluid medium which has as the essential component nicotine in an I amount between 0.1 and 10mg and where the fluid medium has a SI pH of between 7 and r -8- 8 A bite rupturable capsule as claimed in claim 4 where the nicotine in the fluid medium is between 2mg and
6. A bite rupturable capsule according to claim 4 or claim 5 where the volume of the capsule is 0.1 to 1.0 ml.
7. A bite rupturable capsule as claimed in any one of claims 4 to 6 where the capsule filling includes additives to improve the taste and tolerability of the capsule S filling. So Dated this 20th day of January, 1992. e FORSCHUNGSGESELLSCHAFT RAUCHEN UND GESUNDHEIT mbH By their Patent Attorneys Hallidays Z 5 oo *1| e r INTERNATIONAL SEARCH REPORT Internationsl Application No PCT DE 8 7 0 0507 I I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, Indicate all) L According to International Patent Classificaton (IPC) or to both Natlonal Classification and IPC 4 Int.Cl.: A 61 K 31/465; A 61 K 9/48; A 61 K 9/66 II. FIELDS SIARCHED Minimum Documentation Searched 7 Classification System Classification Symbols 4 Int.C1.: A 61 K Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched Ill. DOCUMENTS CONSIDERED TO BE RELEVANT' Category Citation of Document, with Indication, where appropriate, of the relevant passages Relevant to Claim No. 13 Y DE, LU, A, 65929 (BAYER AG) 15 January 1973 1,2,4,5 see the whole document Y BE, A, 899037 (TRENKER) 18 June 1984 1,2,4,5 see the whole document A DE, A, 3241437 (SCHMIDT) 10 May 1984 cited in the application SSpecial categories of cited documents: r' later document published after the international filing date document definin the general state of the art which Is not or priority date and not In conflict with the suDplcation but documen dfn he gner l sa o e cited to understand the principle or theory underlying the considred to be of particular relevance invention earlier document but published on or after tha nternational document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw dol'bts on priority claim(s) or Involve an inventive step which is cited to establish the publiction date of another document of partlcular relevance' the claimed invention citation or other special reaor (as specified) cannot be considered to involve an inventive step when the document referring to an orstdisclosure, use, exhibition or document is combined with one or more other such docu- other means ments, such combination being obvious to a person skilled document published prior to the international filing date but in the art. later than the priority date claimed document member of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search Date of Milling of this International Search Report 14 January 1988 (14.01.88) 17 February 1988 (17.02.88) International 'Srachlng Authority Signature of Authorized Officer European Patent Office Form PCT/ISA/210 (secbond sheet) (January 1985) J .I; -i L -:II If:rr~ i ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. DE 8700507 SA 19381 This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 29/01/88 The European P'atent Office is in no way liable for these particulars ishich are merely given for the purpose of information. P'atent document Publication Patent family Publication cic nsearch report date member(s) date LU-A- 65929 15-01-73 NL-A- 7211565 FR-A,B 2150848 US-A- 3784684 BE-A- 787951 GB-A- 1362627 CA-A- 981582 JP-A- 5319.1921 JP-A- 58113126 JP-A- .58121210 JP-A- 58121211 OE-A,B,C 2209526 AT-B- 328073
27-02-73 13- 04-7 3 08-01-74 26 -02-73 07-08-74 13-0 1-76 24-10-78 05-07-83 19-07-83 19-07-83 06 -09-73 10-03-76 BE-A- 899037 18-06-84 Keine OE-A- 3241437 10-05-84 Keine w For more details about this annex see official journal of the European Patent Office, X4'0 I /82
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863639418 DE3639418A1 (en) | 1986-11-18 | 1986-11-18 | NICOTINE-BASED AGENT |
| DE3639418 | 1986-11-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8171287A AU8171287A (en) | 1988-06-16 |
| AU622101B2 true AU622101B2 (en) | 1992-04-02 |
Family
ID=6314221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU81712/87A Ceased AU622101B2 (en) | 1986-11-18 | 1987-11-06 | Oral administration capsule with a nicotine-containing fluid medium |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0324794B1 (en) |
| JP (1) | JP2602043B2 (en) |
| CN (1) | CN87107852A (en) |
| AT (1) | ATE72114T1 (en) |
| AU (1) | AU622101B2 (en) |
| BR (1) | BR8707879A (en) |
| DE (3) | DE3645036A1 (en) |
| DK (1) | DK173353B1 (en) |
| WO (1) | WO1988003803A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| DE4440563A1 (en) * | 1994-11-12 | 1996-05-15 | Herzog Sen Rolf | Nicotine-contg. media and perfume ointments as substitute for smoking |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| AU2340397A (en) * | 1996-03-21 | 1997-10-10 | Mayo Foundation For Medical Education And Research | Use of nicotine to treat liver disease |
| GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| AUPO108596A0 (en) * | 1996-07-18 | 1996-08-08 | Collier, Gregory | Treatment of obesity |
| US6211194B1 (en) | 1998-04-30 | 2001-04-03 | Duke University | Solution containing nicotine |
| US6268386B1 (en) * | 1998-06-25 | 2001-07-31 | Marshall Anlauf Thompson | Nicotine beverage |
| GB2338896B (en) | 1998-07-02 | 2003-05-21 | Reckitt & Colmann Prod Ltd | Chewable Capsules |
| DE60040293D1 (en) | 1999-07-28 | 2008-10-30 | Univ R | USE OF NICOTIN IN THE ANGIOGENESIS AND THE VASCULOSIS |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| AT409219B (en) * | 1999-08-13 | 2002-06-25 | Red Bull Gmbh | Use of nicotine for producing pharmaceuticals |
| SE0104388D0 (en) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
| ES2708551T3 (en) | 2002-12-20 | 2019-04-10 | Niconovum Ab | Particulate material containing nicotine with a crystalline cellulose |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
| WO2005007068A1 (en) * | 2003-07-22 | 2005-01-27 | The Kiwigel Company Limited | Nicotine packaging system |
| NO20042835D0 (en) * | 2004-07-05 | 2004-07-05 | Nils-Erik Skeide | Encapsulated tobacco smoke |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | Biosynchronous transdermal drug delivery |
| JP5694645B2 (en) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ | Improved snuff composition |
| ES2521494T3 (en) * | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Methods and compositions for reducing the side effects of therapeutic treatments |
| CN101249130B (en) * | 2008-04-11 | 2011-06-15 | 桂林商源植物制品有限公司 | Medicinal or health care combination for stop smoking or alleviating stop smoking syndrome |
| WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| US10568852B2 (en) | 2015-05-22 | 2020-02-25 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Combination compositions and their use in methods for treating obesity and obesity-related disorders |
| CN105341990A (en) * | 2015-12-16 | 2016-02-24 | 浙江中烟工业有限责任公司 | An electronic cigarette liquid that enhances the physiological satisfaction of electronic cigarettes |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| WO2019232077A1 (en) | 2018-05-29 | 2019-12-05 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5173585A (en) * | 1984-12-25 | 1986-07-03 | Tyroler, J. | Flavour capsule |
| AU5427586A (en) * | 1985-03-05 | 1986-10-16 | Ciba-Geigy Ag | Device and methods for treating memory impairment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU432703A3 (en) * | 1971-08-24 | 1974-06-15 | Фридрих Боссерт, Вульф Фатер, Курт Бауер | |
| US3870794A (en) * | 1974-02-20 | 1975-03-11 | Foundation For Behavioral Rese | Treatment of certain emotional disorders with nicotine compounds |
| GB1528391A (en) * | 1976-01-05 | 1978-10-11 | Gildemeister V | Aerosol compositions |
| DE3241437A1 (en) * | 1982-11-10 | 1984-05-10 | Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt | Composition for stopping smoking and/or for intake of nicotine without side effects by addicted smokers |
| GB8301659D0 (en) * | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
| BE899037A (en) * | 1984-02-29 | 1984-06-18 | Trenker Ady | Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt |
| DE3438284A1 (en) * | 1984-10-16 | 1985-03-07 | Hans-Harald von 2400 Lübeck Tilly | Nicotine-containing depot plaster |
-
1986
- 1986-11-18 DE DE19863645036 patent/DE3645036A1/en active Granted
- 1986-11-18 DE DE19863639418 patent/DE3639418A1/en active Granted
-
1987
- 1987-11-06 JP JP62506732A patent/JP2602043B2/en not_active Expired - Lifetime
- 1987-11-06 WO PCT/DE1987/000507 patent/WO1988003803A1/en not_active Ceased
- 1987-11-06 AT AT87907302T patent/ATE72114T1/en not_active IP Right Cessation
- 1987-11-06 DE DE8787907302T patent/DE3776574D1/en not_active Expired - Fee Related
- 1987-11-06 EP EP87907302A patent/EP0324794B1/en not_active Expired - Lifetime
- 1987-11-06 AU AU81712/87A patent/AU622101B2/en not_active Ceased
- 1987-11-06 BR BR8707879A patent/BR8707879A/en not_active Application Discontinuation
- 1987-11-18 CN CN87107852A patent/CN87107852A/en active Pending
-
1988
- 1988-07-08 DK DK198803858A patent/DK173353B1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5173585A (en) * | 1984-12-25 | 1986-07-03 | Tyroler, J. | Flavour capsule |
| AU5427586A (en) * | 1985-03-05 | 1986-10-16 | Ciba-Geigy Ag | Device and methods for treating memory impairment |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1988003803A1 (en) | 1988-06-02 |
| DK173353B1 (en) | 2000-08-07 |
| JPH02501304A (en) | 1990-05-10 |
| DK385888A (en) | 1988-07-08 |
| ATE72114T1 (en) | 1992-02-15 |
| DE3639418A1 (en) | 1988-06-09 |
| EP0324794A1 (en) | 1989-07-26 |
| DE3776574D1 (en) | 1992-03-12 |
| DE3645036A1 (en) | 1989-01-05 |
| DK385888D0 (en) | 1988-07-08 |
| AU8171287A (en) | 1988-06-16 |
| CN87107852A (en) | 1988-06-22 |
| BR8707879A (en) | 1989-10-03 |
| JP2602043B2 (en) | 1997-04-23 |
| EP0324794B1 (en) | 1992-01-29 |
| DE3639418C2 (en) | 1989-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU622101B2 (en) | Oral administration capsule with a nicotine-containing fluid medium | |
| US5298257A (en) | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | |
| Ferguson | Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction | |
| JP5845194B2 (en) | Nicotine-containing soft gelatin troche | |
| Gourlay et al. | Antismoking products | |
| MX2011003984A (en) | Multi portion intra-oral dosage form and use thereof. | |
| US6045825A (en) | Plantago major and Piper methysticum compound for use in treating a tobacco or nicotine habit | |
| US6645470B1 (en) | Treatment and system for nicotine withdrawal | |
| Wongwiwatthananukit et al. | Efficacy of Vernonia cinerea for smoking cessation | |
| RU2445971C2 (en) | Aqueous extract of tobacco leaves and use thereof in treating dependence | |
| US5716635A (en) | Plantago major transdermal patch for use in treating a tobacco or nicotine habit | |
| US9226944B2 (en) | Herbal preparation for sleep apnea relief | |
| WO2018169387A1 (en) | Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction | |
| US5130132A (en) | Composition and method for treating nicotine dependency | |
| CN104548020B (en) | A kind of purposes of pharmaceutical composition in treatment senile dementia is prepared | |
| EP0955053A1 (en) | A plantago major and hypericum perforatum compound for use in treating a tobacco or nicotine habit | |
| JPH09507053A (en) | Use of roberin for the treatment of nicotine withdrawal symptoms | |
| CN1050052C (en) | Habit-breaking acupoint adhesive plaster for smokers | |
| CN114129614B (en) | Application of rabdosia lophanthide in preventing or treating nicotine dependence | |
| JPS6296418A (en) | Medicinal chewing gum | |
| Ostrowski et al. | Pharmacologic management of patients using smoking cessation aids | |
| IE57786B1 (en) | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | |
| Pekgor et al. | 1The Department of Family Medicine, 2The Department of General Surgery and Director of Family Medicine Clinic, Konya Training and Research Hospital, University of Health Sciences, Konya, Turkey | |
| Potter | A Compend of Materia Medica, Therapeutics and Prescription Writing, with Especial Reference to the Physiological Actions of Drugs | |
| CN102885956A (en) | A kind of sleep aid traditional Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |